Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party.

Ali Bazarbachi Myriam Labopin Tobias Gedde-Dahl Peter Remenyi Edouard Forcade Nicolaus Kroeger Gerard Sociè Charles F Craddock Jean Henri Bourhis Jurjen Versluis Ibrahim Yakoub Agha Urpu Salmenniemi Jean El-Cheikh Gesine Bug Aleksandra Holowiecka Arnon Nagler Fabio Ciceri Mohamad Mohty

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In AML patients with FLT3 ITDand wild-type NPM1, we noticed a significant decrease over time in the CIR and improvement of LFS and OS, likely reflecting the efficacy of FLT-3 inhibitors, including when used as post-transplant maintenance, in this high-risk setting. On the contrary, no significant change over time was noticed in outcomes of patients harboring a FLT3 and NPM1 mutation.

Keyphrases

acute myeloid leukemia
wild type
allogeneic hematopoietic stem cell transplantation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
adipose tissue
acute lymphoblastic leukemia
tyrosine kinase
weight loss